Quince Therapeutics, Inc. (QNCX)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - |
| Operating profit | $m | -50 | -124 | ||||||
| Net profit | $m | -77 | -90 | -52 | -31 | -57 | -84 | -92 | - |
| EPS reported | $ | -336.0 | -68.91 | ||||||
| Operating cashflow per share | $ | -165.4 | -7.65 | ||||||
| Capex per share | $ | 1.41 | 0.01 | ||||||
| FCF per share | $ | -166.8 | -7.66 | ||||||
| Free cash flow | $m | -42 | -47 | ||||||
| Net debt | $m | 1 | -116 | ||||||
| Book value equity | $m | -36 | 108 | ||||||
| Book value per share | $ | -142.6 | 17.69 | ||||||
| Number of shares | m | 0.25 | 6.13 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -4.70 | 1.55 | ||||||
| P/S LTM | x | 0.00 | 0.00 | ||||||
| P/FCF LTM | x | -4.02 | -3.57 | ||||||
| EV/EBITDA LTM | x | -2.24 | -2.50 | ||||||
| EV/Sales LTM | x | 0.00 | 0.00 | ||||||
| Earnings Yield LTM | % | -50.04% | -44.30% | ||||||
| FCF Yield | % | -24.89% | -28.01% | ||||||
| Quality | |||||||||
| ROE | % | +235.14% | +681.14% | ||||||
| ROIC | % | -73.69% | -1.04% | ||||||
| Operating margin | % | 0.00% | 0.00% | ||||||
| Gross margin | % | 0.00% | 0.00% | ||||||
| FCF/Sales | % | - | - | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | - | - | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | -2.26 | - | ||||||
| Net Debt/EBITDA | x | -0.16 | 1.51 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +10.94% | 0.00% | ||||||
| Net debt/Equity | x | -0.02 | -1.07 | ||||||
| Gross debt/equity | x | -0.52 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Quince Therapeutics, Inc. (QNCX)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free